Poland· PL-100315321
Rapiscan
A regadenoson product containing regadenosonum, registered in Poland by GE Healthcare AS. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Regadenoson is registered in 13 of 19 countries.
Countries holding a registration under ATC C01EB21 (regadenoson), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Regadenoson · ATC C01EB21
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Regadenosonum
- Manufacturer
- GE Healthcare AS
- Country
- Poland (PL)
- ATC code
- C01EB21
- ATC class
- Regadenoson
- Defined daily dose
- 0.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05060265060008
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for regadenoson.
Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Regadenoson · interactions on record
6 records
- 6 moderate
Most severe, free to view
- DipyridamoleB01AC07moderate
- DipyridamolC01DX29moderate
- TheophyllinC01EB28moderate
- CaffeineN06BC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Regadenoson in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandRapiscan 400 µg/ 5 ml, InjektionslösungGE Healthcare AG
- NorwayRapiscanGE HEALTHCARE AS
- SwedenRapiscan 400 mikrogram/5 ml Injektionsvätska, lösningGE Healthcare AS
- United StatesLEXISCANAstellas Pharma US, Inc.
- FinlandRapiscanGE Healthcare AS
- CzechiaRAPISCANGE Healthcare AS, Oslo
- SpainRapiscan 400mcg solucion inyectableGe Healthcare As
- FranceRAPISCAN 400 microgrammes, solution injectableGE HEALTHCARE (NORVEGE)
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Rapiscan
- Iceland · Rapiscan
- Liechtenstein · Rapiscan
- Norway · Rapiscan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5c44a62-25a7-4713-915d-95108ebafce7 GET /v1/drugs/d5c44a62-25a7-4713-915d-95108ebafce7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "400 mcg/5 ml",
"packaging": "Rpz ¦ EU/1/10/643/001 ¦ 91127\n1 fiol. 5 ml\n¦ UR/Z/4c/036/23 - 05060265060008",
"substance": "Regadenosonum 400 mcg",
"common_name": "Regadenosonum",
"pl_product_id": "100315321",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about regadenoson.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.